Allianz's M&A Spree Puts a Stretched Valuation to the Test

Allianz hits record operating profit but restructuring costs weigh; analysts split on valuation as shares near all-time high.

The market's verdict on Allianz is currently split down the middle. On one side sits a record-breaking operating performance, a fortified capital buffer, and a share price hovering just beneath its all-time high. On the other, a dense pipeline of acquisitions awaiting regulatory clearance, a hefty restructuring charge that clipped quarterly earnings, and a valuation that some analysts believe has already run its course.

The shares closed Tuesday at €442.00, a mere 0.4 percent below the 52-week high of €443.80 struck on August 6. That proximity to peak levels has emboldened a cluster of bulls while leaving a separate camp conspicuously cautious.

A Flurry of Analyst Revisions

The post-earnings commentary has been notably active. Goldman Sachs lifted its price target to €465 from €450 on August 12, reaffirming a "Buy" rating. Two days later, JPMorgan followed with an increase to €460, though it held its stance at "Neutral" — a signal that a higher valuation does not necessarily translate into conviction about further upside. RBC had already adjusted its target from €440 to €450 on August 10, keeping a "Sector Perform" rating.

The dispersion across the Street remains unusually wide. At the optimistic end, Berenberg set a target of €684 following the earnings call, while Jefferies sits at the opposite pole with €325. UBS occupies the middle ground at €430. Those figures date from August 7, the day of the results release, making them older than the more recent upward revisions from the three major banks.

The Numbers Behind the Debate

The fundamental picture is genuinely strong. Allianz posted a record operating result of €4.9 billion in the second quarter and confirmed its full-year guidance of €17.4 billion, plus or minus €1 billion. First-half operating profit climbed 8.6 percent to €9.4 billion, hitting 54 percent of the annual target. Adjusted net income attributable to shareholders rose 15.5 percent to €6.4 billion for the half.

Yet the second quarter told a slightly different story. Reuters noted that the adjusted quarterly profit missed expectations, weighed down by restructuring charges of €643 million. The adjusted net profit attributable to shareholders came in at €2.6 billion, down from €2.841 billion in the same period last year.

The fact that several houses raised their targets only days after the initial release suggests the restructuring costs are being re-evaluated as less damaging than first impressions implied. The confirmation of guidance and robust quarterly business volume of €45.6 billion appears to carry more weight with optimists than the short-term earnings drag.

The Capital Question

What truly underpins the current valuation is a single metric: the Solvency II ratio. At 225 percent as of mid-year, it has climbed 7 percentage points from the full-year 2025 level. That buffer is the reason investors are willing to entertain multiple large acquisitions simultaneously without fearing for the ongoing share buyback program.

Of the planned €2.5 billion in buybacks, €1.4 billion had been deployed by the end of the first half. As long as the solvency ratio holds near current levels, the company can fund acquisitions, repurchases, and dividends in parallel. Should it slip meaningfully — whether through capital outflows tied to the HSBC and UOBAM deals or market turbulence — the credibility of combining expansion with capital returns would quickly erode.

A Pipeline of Deals

The acquisition agenda is ambitious. In early August, asset management arm Allianz Global Investors agreed to acquire UOB Asset Management for approximately $432.7 million, bringing in operations across eight Asian markets and 500 employees. Late July saw the €2.1 billion agreement to purchase HSBC Life Singapore, with completion slated for the first half of 2027. June brought the planned full takeover of Portugal's Caravela for an estimated €150 million.

Skeptics point to the integration density: three parallel deals across different regulatory jurisdictions, plus a separately announced workforce reduction of 1,500 to 1,800 positions globally tied to an AI initiative at Allianz Partners. The HSBC Life and UOBAM transactions remain subject to regulatory approval and are not expected to close until 2027, leaving room for authorities in Singapore or elsewhere to impose conditions that could erode projected synergies.

Technical Signals and the Road Ahead

The chart offers mixed messages. The RSI sits at 63.4, suggesting momentum that is positive but not yet overheated, while the share price stands 14 percent above its 200-day moving average — evidence of a sustained uptrend. The distance to the 50-day average is a tighter 5.4 percent, hinting that short-term upside may be limited.

The stock has climbed 31 percent from its March 52-week low of €337.10, a trajectory that lends support to the more confident analyst camp. Whether the optimistic price targets materialize will likely depend on the restructuring charges dissolving from the balance sheet in coming quarters — and on the regulatory path for the Asian acquisitions.

The next concrete test is progress on the pending approvals for HSBC Life Singapore and UOBAM, both targeted for 2027 completion. Until then, the shares near their record high serve as a referendum on whether record operating results and external growth can coexist indefinitely — or whether one must eventually yield to the other.